Oxaliplatin
Product Images NDC 63323-750

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 63323-750). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxa0p 0001 01

Chemical structure of Oxaliplatin, showing a platinum (Pt) center coordinated with two amine (NH2) groups attached to a cyclohexane ring and two oxalate groups.*

FDA Label Image

Oxa0p 0001 02

A Kaplan-Meier survival curve chart depicting Disease-Free Survival (DFS) probability over time in months. It compares two treatment arms, FOLFOX4 and LV5FU2, with lines indicating DFS probability and corresponding number of events and patients at risk, including annotated hazard ratio and significance test results.*

FDA Label Image

Oxa0p 0001 03

A Kaplan-Meier survival curve graph depicting disease-free survival (DFS) probability over time in months for two treatment arms, FOLFOX4 and LV5FU2, in Stage III patients. The graph includes hazard ratio with confidence interval and p-value from the logrank test, comparing the two treatments' DFS outcomes.*

FDA Label Image

Oxa0p 0001 04

A Kaplan-Meier survival curve showing the percentage of patients surviving over 24 months for three treatment groups: Oxaliplatin with 5-FU/LV, Oxaliplatin with irinotecan, and Irinotecan with 5-FU/LV. The graph includes median survival times in months for each group and a statistical significance value (p<0.0001).*

FDA Label Image

Oxa0p 0001 05

FDA Label Image

Oxa0p 0001 06

Oxaliplatin Injection, USP 50 mg per 10 mL vial (5 mg per mL) by Fresenius Kabi USA, LLC. The label indicates it is for intravenous use only and must be diluted with 5% dextrose injection before use. Storage instructions specify 20° to 25°C, and the vial is single-dose.*

FDA Label Image

Oxa0p 0001 07

The panel for Oxaliplatin Injection, USP shows strength as 50 mg per 10 mL (5 mg per mL). It states intravenous use only, requirement to dilute with 5% dextrose before use, preservative-free status, and warns it is a cytotoxic agent. It advises not to mix with sodium chloride or chloride solutions and indicates single dose vial usage by Fresenius Kabi USA, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.